CORTIJECT®
The posterior segment of the eye is the site of several conditions that lead to blindness, such as age related macular degeneration and diabetic retinopathy.
Diabetic retinopathy and macular edema
One of the major complications resulting from diabetes is diabetic retinopathy, which occurs in 50% of patients and is the leading cause of blindness in working age adults. A main manifestation of diabetic retinopathy includes diabetic macular edema.
Diabetes affects the circulatory system of the retina leading to cause ischemia or oxygen-deprivation. The circulatory system attempts to maintain adequate oxygen levels within affected eye tissues through neovascularization, or the creation of new, fragile blood vessels. These delicate vessels haemorrhage easily, and can impair vision.
In the later phases of the disease, continued abnormal vessel growth and scar tissue may cause serious complications as swelling or edema within the macula and can finally damage central vision leading to blindness.
In diabetic macular edema, the need for innovative and safe products is crucial. Taking into account the significant potential advantages, we are developing an innovative formulation that benefits from the Eyeject® technology.
Nova63035 is an innovative preservative-free and solvent-free emulsion that contains a tissue-activated corticosteroid prodrug. Corticosteroids are potent multi-target agents. Although they are commonly used for treatment of retinopathies, they can trigger steroid-induced side effects such as cataract and glaucoma. As a prodrug activated at the retinal level, our product is intended to efficiently treat macular edema without steroid-induced side effects. Furthermore Nova63035 benefits from Eyeject® advantages which are ease-of-administration for the practitioner as well as prolonged effect and safety for the patient.
Nova63035 has potential applications in other back-of-eye conditions.
